|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.2653 - 0.2970|
|52 Week Range||0.2550 - 3.1850|
|Beta (3Y Monthly)||2.30|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
VANCOUVER, British Columbia, May 15, 2019 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has undertaken steps.
SAN JUAN, Puerto Rico, May 15, 2019 -- Veritas Pharma Puerto Rico, Inc., a wholly owned subsidiary of Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP).
2018 and the first quarter of 2019 has been a transition period for Veritas Pharma, as the company has matured from being purely engaged in research and development to establishing a viable option for cannabis production in Canada, setting the stage for potential commercialization given positive clinical trial results on its lead pain treatment and appointing new leadership to the company.
VANCOUVER, British Columbia, March 04, 2019 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has filed a claim.
CTL-X, supplied by one of Puerto Rico’s notable cannabis performers, the Institute for Medical Cannabis (“IMC”), will be evaluated on its analgesic properties on simulated pain using standardized pain scales. The clinical research organization, Fundación de Investigación (“FDI”), administered the trial drug in the phase II-III unit at their state-of-the-art facility.
Veritas’ director, Nick Standish, commented, “this is an exciting development for Veritas as it further develops our ability to commercialize our proprietary hemp and cannabis products, in addition to expanding our production potential to topical creams and edibles along with oil extracts.
Dr. Franciosi stated, “It has been a challenging year with the regulatory delays in starting the Puerto Rico human study of CTL-X and the need to raise funds for medical cannabis research. I am pleased to see the study approval has finally come through and that potential funding for Cannevert’s important scientific work has been secured, which means that the Veritas and Cannevert are now set for growth under new leadership. Mr. McFadden stated, “The Veritas Board would like to thank Lui for his commitment to investors and to advancing the science behind medical cannabis.” Dr. Franciosi will continue to assist both companies in an operational capacity.
IMC and FDI represent two of Puerto Rico’s leading researchers in medicinal cannabis. The concession is also the first of its kind, representing the first collaboration of such by local partners and a foreign-owned and publicly-traded entity.
VANCOUVER, British Columbia, Feb. 04, 2019 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it is proceeding with a.
Under the terms of the MOU, both companies wish to collaborate in a structured, scientific manner with respect to formally identifying and cooperating on the advancement of medical cannabis strains or cultivars as well as to jointly develop, commercialize and patent protect medicinal products to treat specific diseases and chronic conditions. Veritas’ CEO, Dr. Lui Franciosi stated, “Santa Marta will enable the scientists at Cannevert Therapeutics Ltd. (“CTL”) to obtain a variety of cannabis strains in the near future with the aim of discovering and developing proprietary products that have consistent and optimal clinical effects. This will be another example of a great partnership for the science and business of medical cannabis”.
VANCOUVER, British Columbia, Dec. 21, 2018 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that the.
Blair is a corporate lawyer with many years of experience working with public companies, particularly in the cannabis industry. Blair is excited to help ensure the continued integrity of the Company’s governance framework, administration and regulatory compliance.
VANCOUVER, British Columbia, Nov. 14, 2018 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that it has.
CTL-X is a unique cannabis strain mix which has so far demonstrated evidence of reducing acute pain. CTL-X is the culmination of two years of preclinical testing by the Company’s research arm, Cannevert Therapeutics Ltd. (“Cannevert”), located at the University of British Columbia.
VANCOUVER, British Columbia, Nov. 06, 2018 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce the Closing of.